Cargando…

Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus

BACKGROUND: It has been reported that several baseline polymorphisms of direct-acting antivirals (DAAs) agents resistance-associated variants (RAVs) would affect the treatment outcomes of patients chronically infected with hepatitis C virus (CHC). The aim of this study is to investigate the prevalen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ye, Rao, Hui-Ying, Xie, Xing-Wang, Wei, Lai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736847/ https://www.ncbi.nlm.nih.gov/pubmed/26415801 http://dx.doi.org/10.4103/0366-6999.166038

Ejemplares similares

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
por: Zanaga, L.P., et al.
Publicado: (2016)

Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients
por: Li, Zhanyi, et al.
Publicado: (2017)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
por: Wang, Yadong, et al.
Publicado: (2022)

Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China
por: Li, Zhao, et al.
Publicado: (2017)

Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China
por: Wang, Xiaozhong, et al.
Publicado: (2021)

Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis
por: Suwanthawornkul, Thanthima, et al.
Publicado: (2015)

Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
por: Lee, Hyun Woong, et al.
Publicado: (2017)

Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China
por: Li, Zhanyi, et al.
Publicado: (2017)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1
por: Zhu, Gui-Qi, et al.
Publicado: (2016)

Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Direct-acting antiviral agents against hepatitis C virus and lipid metabolism
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus
por: Fawsitt, Christopher G., et al.
Publicado: (2019)

Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents
por: Minosse, Claudia, et al.
Publicado: (2018)

Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
por: John, Jason J., et al.
Publicado: (2021)

Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents
por: Xiao, Fei, et al.
Publicado: (2014)

Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis
por: Yen, Hsu-Heng, et al.
Publicado: (2022)

Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection
por: Mei, Yong-yu, et al.
Publicado: (2020)

Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
por: Toshikuni, Nobuyuki
Publicado: (2017)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
por: Ghweil, Ali A, et al.
Publicado: (2019)

SASLT Position Statement on the Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection
por: Alghamdi, Abdullah S., et al.
Publicado: (2015)

Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates
por: Gadiparthi, Chiranjeevi, et al.
Publicado: (2018)

Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan
por: Khaliq, Saba, et al.
Publicado: (2018)

Racial/Ethnic and Socioeconomic Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus in an Insured Population
por: Marcus, Julia, et al.
Publicado: (2017)

Direct‐acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta‐analysis
por: Liu, Jiaye, et al.
Publicado: (2019)

Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients
por: Fouad, Magdy, et al.
Publicado: (2021)

Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease
por: Fabrizi, Fabrizio, et al.
Publicado: (2022)

Mechanisms of Action of the Host-Targeting Agent Cyclosporin A and Direct-Acting Antiviral Agents against Hepatitis C Virus
por: Liu, Dandan, et al.
Publicado: (2023)

Hypozincemia in Chronic Hepatitis C Is Improved with Viral Clearance by Direct-acting Antiviral Agents
por: Shirahashi, Ryosaku, et al.
Publicado: (2021)

Factors Associated with the Refusal of Direct-Acting Antiviral Agents for the Treatment of Hepatitis C in Taiwan
por: Chang, Li-Jen, et al.
Publicado: (2022)

The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection
por: Dawood, Reham M, et al.
Publicado: (2022)

Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?
por: Nemteanu, Roxana, et al.
Publicado: (2023)

Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents
por: Cholankeril, George, et al.
Publicado: (2017)

Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients
por: Cheng, Chun-Han, et al.
Publicado: (2022)

Effect of Direct-Acting Antiviral Agents on Gastroesophageal Varices in Patients with Hepatitis C Virus-Related Cirrhosis
por: Hisanaga, Hiroshi, et al.
Publicado: (2022)

Resolution of refractory hepatic hydrothorax in patients with hepatitis C virus cirrhosis after treatment with direct-acting antiviral agents
por: Hussein, Maged H., et al.
Publicado: (2018)

Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Economic evaluation of direct‐acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore
por: Wong, Yu‐Jun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_18c85hp9cokleqp6c28hloolt1